H.C. Wainwright analyst Joseph Pantginis has reiterated their bullish stance on CMPX stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily the strength of tovecimig’s progression-free survival data in second-line biliary tract cancer. He highlights that the regimen meaningfully lengthens the time patients live without disease worsening versus standard chemotherapy and even exceeds a key historical benchmark, indicating clinically relevant benefit that he believes the market is undervaluing.
At the same time, Pantginis views the overall-survival readout as confounded rather than negative, given the high crossover rate from the control arm to tovecimig, and points to exploratory analyses and PFS2 data as supportive of true drug activity. He therefore interprets the recent share weakness as driven by regulatory uncertainty, not by a failure of the drug, and maintains an unchanged $24 price target based on the potential for a successful FDA dialogue, a planned BLA submission around year-end 2026, and a possible U.S. approval in 2027.